The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | Unmet needs in PTCL: improving frontline therapy and personalizing treatment
Neha Mehta-Shah, MD, MSCI, Washington University, St Louis, MO, discusses the key unmet needs in the peripheral T-cell lymphoma (PTCL) space. She emphasizes the need for improved frontline therapy options, as well as the development of markers to identify which patients will benefit from specific treatments. These advances will allow clinicians to personalize treatment to meet patient-specific needs. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
NMS has served as a consultant for Kyowa Hakko Kirin, Secura Bio, AstraZeneca, Genentech/Roche, Janssen Oncology. NMS has institutional research funding from Bristol Myers Squibb (Inst), Genentech/Roche (Inst), Celgene (Inst), Verastem (Inst), Innate Pharma (Inst), Corvus Pharmaceuticals (Inst), AstraZeneca (Inst), C4 Therapeutics (Inst), Daiichi Sankyo (Inst), Yingli Pharma (Inst), Dizal Pharma (Inst), Secura Bio (Inst), Morphosys (Inst). She is supported by the Leukemia Lymphoma Society as a Scholar in Clinical Research.
